Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada.
The last earnings update was 151 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Hemostemix. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Hemostemix's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemostemix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Hemostemix's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Hemostemix's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Hemostemix's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Hemostemix is high growth as no earnings estimate data is available.
Unable to determine if Hemostemix is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hemostemix's filings and announcements here.
Hemostemix's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Kyle Makofka Co-Founded Drive Capital Corporation in 2012 and served as its Principal. Mr. Makofka has been Chief Executive Officer at Hemostemix Inc., since November 30, 2017 and served as its President since November 30, 2017 until April 2019. He served as the Chief Restructuring Officer of Hemostemix Inc. from January 25, 2017 to November 30, 2017. Mr. Makofka served as President of Victory Rig Equipment Corporation. Mr. Makofka has over 27 years of oilfield industry experience and has worked in all facets of the oil and gas industry including field operations, dispatch, quality assurance, health and safety, marketing, supervising and manufacturing. He served as General Manager at High Arctic Energy Service Inc. He founded Victory Energy Rentals in 2004. He served as Partner of Exact Canada Industries. He served as Partner of Flame Industries. He founded Quantum Petrophysics. Mr. Makofka served as General Manager for one of Canada 's Top 50 Best Managed Companies. and Project Manager for multiple Rig Projects and Prototype Construction. Mr. Makofka was Work-over Completion Foreman for major Oil and Gas Producers and involved in various Oilfield operations from Argentina to Alaska and the Middle East. He is I.S.O. 9001/2000 Implementation Leader for major service company. Mr. Makofka's companies have been featured in Alberta Venture Magazine's Fastest Growing List and one was also a finalist for the Red Deer Chamber of Commerce Business of the Year Award. Mr. Makofka has International Well Control Certification.
Insufficient data for Kyle to compare compensation growth.
Kyle's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Hemostemix management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Chief Financial Officer
Director of Operations
Chief Medical Consultant
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Hemostemix board of directors is less than 3 years, this suggests a new board.
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.